Market Research Logo

Apolipoprotein A I (APOA1) - Pipeline Review, H2 2016

Apolipoprotein A I (APOA1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Apolipoprotein A I (APOA1) - Pipeline Review, H2 2016’, provides in depth analysis on Apolipoprotein A I (APOA1) targeted pipeline therapeutics.

The report provides comprehensive information on the Apolipoprotein A I (APOA1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Apolipoprotein A I (APOA1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Apolipoprotein A I (APOA1)
  • The report reviews Apolipoprotein A I (APOA1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Apolipoprotein A I (APOA1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Apolipoprotein A I (APOA1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Apolipoprotein A I (APOA1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Apolipoprotein A I (APOA1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Apolipoprotein A I (APOA1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Apolipoprotein A I (APOA1) Overview
Therapeutics Development
Apolipoprotein A I (APOA1) - Products under Development by Stage of Development
Apolipoprotein A I (APOA1) - Products under Development by Therapy Area
Apolipoprotein A I (APOA1) - Products under Development by Indication
Apolipoprotein A I (APOA1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Apolipoprotein A I (APOA1) - Products under Development by Companies
Apolipoprotein A I (APOA1) - Products under Development by Universities/Institutes
Apolipoprotein A I (APOA1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Apolipoprotein A I (APOA1) - Companies Involved in Therapeutics Development
Arisaph Pharmaceuticals, Inc.
Cerenis Therapeutics Holding SA
CSL Limited
Esperion Therapeutics, Inc.
KineMed, Inc.
Apolipoprotein A I (APOA1) - Drug Profiles
4-WF - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARI-1778 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CER-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CER-522 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSL-112 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-4F - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KM-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Apolipoprotein A I (APOA1) - Dormant Projects
Apolipoprotein A I (APOA1) - Discontinued Products
Apolipoprotein A I (APOA1) - Featured News & Press Releases
Sep 01, 2016: Positive safety and tolerability profile of CER-001 presented at the European Society of Cardiology Congress 2016
Aug 30, 2016: Completion of patient enrolment in the CARAT study - meeting the clinical schedule
Jun 02, 2016: Publication of the LOCATION Clinical Study Results in the Renowned Scientific Journal of the European Atherosclerosis Society (EAS)
Jan 28, 2016: Catalent Biologics And Cerenis Therapeutics Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx Cell Line Technology
Nov 10, 2015: Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association Conference 2015
Sep 08, 2015: First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients
Jul 15, 2015: Cerenis Therapeutics Announces the Results of the LOCATION Study
Nov 18, 2014: CSL112 Found to Elevate Cholesterol Efflux in Patients with Coronary Artery Disease and Mechanism for Rapid Cholesterol Efflux Capacity Demonstrated
Nov 12, 2014: CSL Launches AEGIS-I, a Phase 2b Clinical Study of CSL112, a Novel Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque
Sep 03, 2014: Cerenis Receives EMA Orphan Drug Designations for CER-001 for the Treatment of ApoA-I and ABCA-1 Deficiencies
Jun 02, 2014: Cerenis Reports Two Positive Phase II Studies for HDL Mimetic CER-001 at EAS
Jan 02, 2014: Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001
Nov 21, 2013: CSL releases positive data for potential new heart attack therapy and announces next phase of clinical development
Nov 05, 2012: Novel Apolipoprotein A-I Therapy, CSL112, May Represent New Option For Reducing Recurrent Heart Attack Risk, Early CSL Studies Show
Mar 15, 2011: Cerenis Initiates Phase II Study Of CER-001 In Acute Coronary Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016
Pipeline by Cerenis Therapeutics Holding SA, H2 2016
Pipeline by CSL Limited, H2 2016
Pipeline by Esperion Therapeutics, Inc., H2 2016
Pipeline by KineMed, Inc., H2 2016
Dormant Projects, H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report